Wed. Jan 26th, 2022

The week left to a strong start on Monday but momentum is currently waning, with European stocks a little flat and US futures only partially greater.
Financiers were eager to purchase dips at the start of the week and capitalise on last weeks sell-off, as China successfully included the infection break out and the FDA gave full approval to the Pfizer-BioNTech vaccine. Chinese growth fears had weighed on threat appetite in recent weeks but it seems the drastic technique is paying off once more.
This offered some relief yesterday, particularly in commodity markets which soared on the back of the news. While a very positive advancement, other nations are taking a much less rigorous method and cases are rising which will likely weigh on growth into completion of the year.
Vaccine efforts should ensure full lockdowns are a distant memory for a lot of these nations but the healing will no doubt sluggish, regardless, as some limitations are imposed and behaviours modification.

By

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Wizadclick | WAC MAG 2022